First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.

被引：1

作者：

Csoszi, Tibor

Powles, Thomas

Alva, Ajjai Shivaram

Castellano, Daniel E.

Ozguroglu, Mustafa

O'Donnell, Peter H.

Loriot, Yohann

Hahn, Noah M.

Flechon, Aude

Rodriguez-Vida, Alejo

De Wit, Ronald

Cheng, Susanna Y.

Oudard, Stephane

Vulsteke, Christof

Yu, Evan Y.

Lin, Jianxin

Imai, Kentaro

Moreno, Blanca Homet

Balar, Arjun Vasant

Grivas, Petros

机构：

[1] Hetenyi Geza Hosp, County Oncol Ctr, Szolnok, Hungary

[2] Queen Mary Univ London, Barts Canc Ctr, London, England

[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA

[4] Univ Hosp October 12, Madrid, Spain

[5] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey

[6] Univ Chicago, Chicago, IL 60637 USA

[7] Gustave Roussy, Canc Campus, Villejuif, France

[8] Univ Paris Saclay, Villejuif, France

[9] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[10] Ctr Leon Berard, Lyon, France

[11] Hosp Mar, Barcelona, Spain

[12] Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, Rotterdam, Netherlands

[13] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[14] Georges Pompidou European Hosp, Paris, France

[15] Univ Antwerp, Maria Middelares, Integrated Canc Ctr Ghent, Ghent, Belgium

[16] Univ Antwerp, Ctr Oncol Res CORE, Ghent, Belgium

[17] Univ Washington, Seattle, WA 98195 USA

[18] Fred Hutchinson Canc Ctr, Seattle, WA USA

[19] Merck & Co Inc, Kenilworth, NJ USA

[20] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[21] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.521

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

521

引用

页数：3